project id: TCGA-BLCA; case submitter id: TCGA-XF-AAMW; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.9; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.01; rna integrity number: 9.0; age at index: 79; days to birth: -28903; days to death: 253; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Dead; year of birth: 1927; year of death: 2006; age at diagnosis: 28903; ajcc pathologic n: N0; ajcc pathologic stage: Stage IV; ajcc pathologic t: T2b; ajcc staging system edition: 5th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2006; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 2682; days to sample procurement: 0; initial weight: 640.0; portion submitter id: TCGA-XF-AAMW-01A-11; percent lymphocyte infiltration: 30.0; percent monocyte infiltration: 70.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 30.0; percent tumor cells: 60.0; percent tumor nuclei: 70.0;